Human mesenchymal stem cell derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure

The therapeutic approaches for chronic kidney disease (CKD) have been able to reduce proteinuria, but not diminish the disease progression. We have demonstrated beneficial effects by injection of bone marrow derived mesenchymal stem cells (BM-MSCs) from healthy donors in a rat model of CKD. However, it has recently been reported that BM-MSCs derived from uremic patients failed to confer functional protection in a similar model. This suggests that autologous BM-MSCs are not suitable for the treatment of CKD. In the present work, we have explored the potential of MSC derived from adipose tissue (AD-MSCs) as an alternative source of MSCs for the treatment of CKD. We have isolated AD-MSCs and evaluated their effect on the progression of CKD. Adult male Sprague-Dawley rats submitted to 5/6 nephrectomy (NPX) received a single intravenous infusion of 0.5x106 AD-MSCs or the MSC conditioned medium alone. The therapeutic effect was evaluated by plasma creatinine measurement, structural analysis and angiogenic/epitheliogenic protein expression. AD-MSCs were detected in kidney tissues from NPX animals. This group presented a significant reduction of plasma creatinine levels and a lower expression of damage markers ED-1 and a-SMA (p<0.05). In addition, treated rats exhibited a higher presence of epitheliogenic (Pax-2, BMP-7) and angiogenic proteins (VEGF). The expression of these biomarkers of regeneration was significantly related to the improvement in renal function. While many as...
Source: Clinical Science - Category: Biomedical Science Authors: Source Type: research